20 Background: The results of the 5-year overall survival (OS) in patients with metastatic
renal cell carcinoma (mRCC) has been reported rarely. The aim of the RENSUR5 registry …

Background The 5-year overall survival (OS) of patients with metastatic renal cell carcinoma
(mRCC) has been rarely reported. The aim of the RENSUR5 registry study was to obtain …

Background Real‐world data describing outcomes of treatment among metastatic renal cell
carcinoma (mRCC) patients are limited and heterogeneous. Aim RENSUR3 registry study …

389 Background: This retrospective register study assessed OS in all mRCC patients in
Sweden diagnosed before (2000–2005) and after (2006–2008) the introduction of targeted …

Results Median OS and one-, three-and five-year OS rates were not reached and 88.7%,
64.9%, and 64.9% in patients treated in 2016-2020; 31.4 months and 78.5%, 42.8% and …

Background This retrospective study investigated overall survival (OS) and factors
influencing OS in Swedish patients with metastatic renal cell carcinoma (mRCC) during the …

Simple Summary The management of metastatic renal cell carcinoma (mRCC) represents a
clinical challenge. Progression or toxicity may occur during first-line treatments and many …

Background The current available evidence on the management of metastatic renal cell
cancer (mRCC) in real life is scarce in our environment. We present a summary of the …

Data on the outcomes of third-or fourth-line therapy for metastatic renal cell carcinoma
(mRCC) are limited. The aim of our study was to evaluate the efficacy of therapy beyond the …

AIM: Patterns of care for metastatic renal cell carcinomas (mRCC) have seen tremendous
reform in the last decade. Here, we present our pattern of care in second-line targeted …